Eyetech Vision Day to Preview Future of Macugen Franchise

Share Name	Share Symbol	Market	Type
Eyetech Pharmaceuticals (MM)	NASDAQ:EYET	NASDAQ	Common Stock

Share Name

Share Symbol

Market

Type

Eyetech Pharmaceuticals (MM)

NASDAQ:EYET

NASDAQ

Common Stock

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

Eyetech Vision Day to Preview Future of Macugen Franchise

21/06/2005 8:33pm

PR Newswire (US)

Eyetech (NASDAQ:EYET)
Historical Stock Chart

From Feb 2020 to Feb 2025

Eyetech Vision Day to Preview Future of Macugen Franchise Top Eyetech Executives and Ophthalmology Researchers to Present at Event This Wednesday, June 22, at 11:45 A.M. NEW YORK, June 21 /PRNewswire-FirstCall/ -- WHEN: Wednesday, June 22 NEW time: 11:45 a.m. to 2:30 p.m. Eastern time* *Please join us for lunch at 11:45 a.m. Presentations will begin promptly at 12:15 p.m. WHERE: The Westin New York Hotel at Times Square 270 West 43rd Street (at 8th Avenue), New York City Broadway Ballroom (third floor) WHAT: Eyetech Pharmaceuticals, makers of Macugen(R) (pegaptanib sodium injection) -- the first anti-VEGF therapy indicated for the treatment of all subtypes of neovascular AMD -- will present details about the Macugen franchise and novel therapies in the pipeline. WHO: Information will be presented by top scientific researchers and senior corporate executives, including: * Anthony P. Adamis, M.D., Executive Vice President of Research and Development and Chief Scientific Officer of Eyetech * Donald D'Amico, M.D., Professor of Ophthalmology at the Massachusetts Eye and Ear Infirmary at Harvard Medical School, and a member of the Eyetech Scientific Advisory Board * Errol De Souza, Ph.D., President and Chief Executive Officer of Archemix Corp. * David R. Guyer, M.D., Chief Executive Officer of Eyetech * Donald McDonald, M.D., Ph.D., Professor of Anatomy, University of California at San Francisco Comprehensive Cancer Center * David Shima, Ph.D., Senior Vice President of Research and Preclinical Development at Eyetech If you are unable to attend in person, you can access a live audio Web cast of the presentation by logging on to the Investor Relations section at http://www.eyetech.com/, or hear the audio portion of the Web cast by dialing 888-275-0218 (in the United States) or 706-679-7756 (internationally). (Logo: http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGO) http://www.newscom.com/cgi-bin/prnh/20050407/EYETLOGODATASOURCE: Eyetech Pharmaceuticals CONTACT: Susan Silao of Eyetech, +1-212-824-3175, ; or Shelly Nelson of Edelman for Eyetech Pharmaceuticals +1-212-819-4845, Web site: http://www.eyetech.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

EYET Eyetech Pharmaceuticals (MM)